# Canagliflozin - Another Top Longevity Drug **URL:** \ **Category:** General\ **Created:** [October 23, 2021, 6:22pm UTC](https://www.rapamycin.news/t/canagliflozin-another-top-longevity-drug/91 "2021-10-23T18:22:56Z")\ **Posts on this page:** 20\ **Page:** 2
**Author:** ![RapAdmin](https://www.rapamycin.news/user_avatar/www.rapamycin.news/rapadmin/32/377_2.png) [@RapAdmin](https://www.rapamycin.news/u/RapAdmin)\ **Post date:** [March 21, 2022, 1:08am UTC](https://www.rapamycin.news/t/canagliflozin-another-top-longevity-drug/91/21 "2022-03-21T01:08:04Z")
A new SGLT2 inhibitor paper (open access): > Sodium-glucose-cotransporter 2 inhibitors (SGLT2is) demonstrate large cardiovascular benefit in both diabetic and non-diabetic, acute and chronic heart failure patients. These inhibitors have on-target (SGLT2 inhibition in the kidney) and off-target effects that likely both contribute to the reported cardiovascular benefit. Here we review the literature on direct effects of SGLT2is on various cardiac cells and derive at an unifying working hypothesis. SGLT2is acutely and directly (1) inhibit cardiac sodium transporters and alter ion homeostasis, (2) reduce inflammation and oxidative stress, (3) influence metabolism, and (4) improve cardiac function. > **[Direct cardiac effects of SGLT2 inhibitors - Cardiovascular Diabetology](https://link.springer.com/article/10.1186/s12933-022-01480-1)** > > Sodium-glucose-cotransporter 2 inhibitors (SGLT2is) demonstrate large cardiovascular benefit in both diabetic and non-diabetic, acute and chronic heart failure patients. These inhibitors have on-target (SGLT2 inhibition in the kidney) and off-target... ---
**Author:** ![AlexKChen](https://www.rapamycin.news/user_avatar/www.rapamycin.news/alexkchen/32/385_2.png) [@AlexKChen](https://www.rapamycin.news/u/AlexKChen)\ **Post date:** [March 28, 2022, 9:24am UTC](https://www.rapamycin.news/t/canagliflozin-another-top-longevity-drug/91/22 "2022-03-28T09:24:47Z")
empagliflozin is way better - [Cost-effectiveness of empagliflozin versus canagliflozin, dapagliflozin, or standard of care in patients with type 2 diabetes and established cardiovascular disease - PMC](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8098979/) ---
**Author:** ![RapAdmin](https://www.rapamycin.news/user_avatar/www.rapamycin.news/rapadmin/32/377_2.png) [@RapAdmin](https://www.rapamycin.news/u/RapAdmin)\ **Post date:** [April 3, 2022, 11:26pm UTC](https://www.rapamycin.news/t/canagliflozin-another-top-longevity-drug/91/23 "2022-04-03T23:26:35Z")
Another new SGLT2i study with good results 😃 > **[Empagliflozin improves cognitive impairment in frail diabetics with HFpEF: Study](https://medicaldialogues.in/diabetes-endocrinology/news/empagliflozin-improves-cognitive-impairment-in-frail-diabetics-with-hfpef-study-90749)** > > Italy: SGLT2 inhibitor empagliflozin improves cognitive and physical impairment in frail older adults with type 2 diabetes and heart failure with preserved ejection fraction (HFpEF), a recent Full Paper: > **[Empagliflozin Improves Cognitive Impairment in Frail Older Adults With Type 2...](https://diabetesjournals.org/care/article-abstract/doi/10.2337/dc21-2434/144737/Empagliflozin-Improves-Cognitive-Impairment-in?redirectedFrom=fulltext)** > > OBJECTIVE. To assess whether the sodium–glucose cotransporter 2 (SGLT2) inhibitor empagliflozin improves cognitive impairment in frail older adults with diabete ---
**Author:** ![RapAdmin](https://www.rapamycin.news/user_avatar/www.rapamycin.news/rapadmin/32/377_2.png) [@RapAdmin](https://www.rapamycin.news/u/RapAdmin)\ **Post date:** [May 20, 2022, 11:02pm UTC](https://www.rapamycin.news/t/canagliflozin-another-top-longevity-drug/91/24 "2022-05-20T23:02:55Z")
[https://twitter.com/AndreeaNRD/status/1527761470292893701?s=20&t=qCCm3zbtWVoTZhXI-vqsCg](https://twitter.com/AndreeaNRD/status/1527761470292893701?s=20&t=qCCm3zbtWVoTZhXI-vqsCg) > **Results:** Compared with placebo, canagliflozin 100 mg reduced SBP by 3.43 mmHg and DBP by 1.05 mmHg. Canagliflozin 100 mg increased LDL-C by 0.10mmol/l and HDL cholesterol (HDL-C) by 0.05 mmol/l. Compared with placebo, canagliflozin 300 mg reduced SBP by 4.75 mmHg and DBP by 1.69 mmHg. Canagliflozin 300 mg increased LDL-C by 0.16 mmol/l and HDL-C by 0.06 mmol/l. Compared with canagliflozin 100 mg, canagliflozin 300 mg further reduced SBP by 1.21 mmHg and DBP by 0.64 mmHg, and further increased LDL-C by 0.06 mmol/l and HDL-C by 0.02 mmol/l. Compared with placebo and canagliflozin 100 mg, canagliflozin 300 mg increased the risk of UTI. > > **Conclusion:** The current meta-analysis provides new evidence on different doses of canagliflozin as an antihypertensive agent in T2DM complicated by hypertension; however, LDL-C and the risk of UTI should be monitored. [https://pubmed.ncbi.nlm.nih.gov/35221325/](https://pubmed.ncbi.nlm.nih.gov/35221325/) ---
**Author:** ![RapAdmin](https://www.rapamycin.news/user_avatar/www.rapamycin.news/rapadmin/32/377_2.png) [@RapAdmin](https://www.rapamycin.news/u/RapAdmin)\ **Post date:** [May 24, 2022, 7:00pm UTC](https://www.rapamycin.news/t/canagliflozin-another-top-longevity-drug/91/25 "2022-05-24T19:00:44Z")
> “Then they evaluated how treatment with the sodium glucose co-transporter 2 (SGLT2) inhibitor empagliflozin (Empa) improved blood vessel function and reduced arterial stiffness in aged male mice.” > **[Drug that lowers blood sugar also reduces blood vessel dysfunction caused by...](https://medicalxpress.com/news/2022-05-drug-lowers-blood-sugar-vessel.html)** > > An FDA-approved drug to lower blood sugar in adults with type 2 diabetes also may decrease blood vessel dysfunction associated with aging, according to a new study from the University of Missouri School of Medicine. ---
**Author:** ![RapAdmin](https://www.rapamycin.news/user_avatar/www.rapamycin.news/rapadmin/32/377_2.png) [@RapAdmin](https://www.rapamycin.news/u/RapAdmin)\ **Post date:** [May 24, 2022, 9:48pm UTC](https://www.rapamycin.news/t/canagliflozin-another-top-longevity-drug/91/26 "2022-05-24T21:48:42Z")
More new research: ## SGLT-2i vs. Metformin: ### Cardiovascular Outcomes in Patients Initiating First-Line Treatment of Type 2 Diabetes With Sodium–Glucose Cotransporter-2 Inhibitors Versus Metformin > ##### Limitation: > > Treatment selection was not randomized. > > ##### Conclusion: > > As first-line T2D treatment, initiators receiving SGLT-2i showed a similar risk for MI/stroke/mortality, lower risk for HHF/mortality and HHF, and a similar safety profile except for an increased risk for genital infections compared with those receiving metformin. [https://www.acpjournals.org/doi/10.7326/M21-4012](https://www.acpjournals.org/doi/10.7326/M21-4012) ---
**Author:** ![Davin8r](https://www.rapamycin.news/user_avatar/www.rapamycin.news/davin8r/32/30524_2.png) [@Davin8r](https://www.rapamycin.news/u/Davin8r)\ **Post date:** [May 24, 2022, 10:50pm UTC](https://www.rapamycin.news/t/canagliflozin-another-top-longevity-drug/91/27 "2022-05-24T22:50:00Z")
Importantly, mean follow up was only 12 months. Since CVD development is a slow process, I’d only expect those relative risks of heart failure to further diverge (and maybe even see some lowered comparative risks for stroke/MI in the SGLT2i group?) as time goes on. Hopefully they’ll continue to follow these cohorts to see if that’s true. I wonder what the relative rate of genital infections in men vs women was in the SGLT2i group? ---
**Author:** ![RapAdmin](https://www.rapamycin.news/user_avatar/www.rapamycin.news/rapadmin/32/377_2.png) [@RapAdmin](https://www.rapamycin.news/u/RapAdmin)\ **Post date:** [May 24, 2022, 11:15pm UTC](https://www.rapamycin.news/t/canagliflozin-another-top-longevity-drug/91/28 "2022-05-24T23:15:24Z")
> [@Davin8r](#): > > I wonder what the relative rate of genital infections in men vs women was in the SGLT2i group? Yes - I have also wondered about this.. I’ve never heard of men getting UTIs, so I suspect its almost all women. But if someone knows differently, please post. ---
**Author:** ![MAC](https://www.rapamycin.news/user_avatar/www.rapamycin.news/mac/32/7620_2.png) [@MAC](https://www.rapamycin.news/u/MAC)\ **Post date:** [May 25, 2022, 12:34am UTC](https://www.rapamycin.news/t/canagliflozin-another-top-longevity-drug/91/29 "2022-05-25T00:34:38Z")
@RapAdmin I think you’re taking SGLT2i for longevity, correct? Have you had a chance to track say phenoage or any other longevity improvement marker? Liver or kidney function? ---
**Author:** ![RapAdmin](https://www.rapamycin.news/user_avatar/www.rapamycin.news/rapadmin/32/377_2.png) [@RapAdmin](https://www.rapamycin.news/u/RapAdmin)\ **Post date:** [May 25, 2022, 12:43am UTC](https://www.rapamycin.news/t/canagliflozin-another-top-longevity-drug/91/30 "2022-05-25T00:43:07Z")
Its all been largely unchanged during time on Sglt2 inhibitors. ---
**Author:** ![brandy111](https://www.rapamycin.news/letter_avatar_proxy/v4/letter/b/f08c70/32.png) [@brandy111](https://www.rapamycin.news/u/brandy111)\ **Post date:** [May 25, 2022, 6:23am UTC](https://www.rapamycin.news/t/canagliflozin-another-top-longevity-drug/91/31 "2022-05-25T06:23:17Z")
Have you noticed any PhenoAge changes during your time on rapamycin? ---
**Author:** ![RapAdmin](https://www.rapamycin.news/user_avatar/www.rapamycin.news/rapadmin/32/377_2.png) [@RapAdmin](https://www.rapamycin.news/u/RapAdmin)\ **Post date:** [May 25, 2022, 4:05pm UTC](https://www.rapamycin.news/t/canagliflozin-another-top-longevity-drug/91/32 "2022-05-25T16:05:38Z")
My phenotypic age is about 15 years lower than my chronological age but i did not test prior to starting rapamycin. ---
**Author:** ![RapAdmin](https://www.rapamycin.news/user_avatar/www.rapamycin.news/rapadmin/32/377_2.png) [@RapAdmin](https://www.rapamycin.news/u/RapAdmin)\ **Post date:** [May 25, 2022, 7:35pm UTC](https://www.rapamycin.news/t/canagliflozin-another-top-longevity-drug/91/33 "2022-05-25T19:35:48Z")
More SGLT2 inhibitor developments: > > **[Dapagliflozin partially restores reproductive function in MC4R KO obese...](https://joe.bioscientifica.com/view/journals/joe/aop/joe-21-0449/joe-21-0449.xml)** > > Obese women often have certain degree of reproductive dysfunction with infertility. Although the clinical impact of obesity on female infertility has been extensively studied, the effective and targeted treatment is still lacking.... ---
**Author:** ![Sasa\_Loncar](https://www.rapamycin.news/user_avatar/www.rapamycin.news/sasa_loncar/32/1990_2.png) [@Sasa\_Loncar](https://www.rapamycin.news/u/Sasa_Loncar)\ **Post date:** [May 26, 2022, 1:03pm UTC](https://www.rapamycin.news/t/canagliflozin-another-top-longevity-drug/91/34 "2022-05-26T13:03:47Z")
> [@RapAdmin](#): > > have the same issue as you with acarbose - a lot of gas most of the time, so its far from optimal. I dont know if you listen to Rich Miller ( ITP Researcher ) on the subject of bloating. Its happens with wheat and I guess all gluten based grains. Rice based population use acarbose with no problem ( Asian population ). ---
**Author:** ![AlexKChen](https://www.rapamycin.news/user_avatar/www.rapamycin.news/alexkchen/32/385_2.png) [@AlexKChen](https://www.rapamycin.news/u/AlexKChen)\ **Post date:** [May 26, 2022, 3:31pm UTC](https://www.rapamycin.news/t/canagliflozin-another-top-longevity-drug/91/35 "2022-05-26T15:31:56Z")
lol i’ve had ZERO side effects with acarbose (but I use them on wheat) ---
**Author:** ![RapAdmin](https://www.rapamycin.news/user_avatar/www.rapamycin.news/rapadmin/32/377_2.png) [@RapAdmin](https://www.rapamycin.news/u/RapAdmin)\ **Post date:** [May 29, 2022, 6:33am UTC](https://www.rapamycin.news/t/canagliflozin-another-top-longevity-drug/91/36 "2022-05-29T06:33:59Z")
> **[Drug That Lowers Blood Sugar Also Reduces Blood Vessel Dysfunction Caused by...](https://medicine.missouri.edu/news/drug-lowers-blood-sugar-also-reduces-blood-vessel-dysfunction-caused-aging)** > > An FDA-approved drug to lower blood sugar in adults with Type 2 diabetes also may decrease blood vessel dysfunction associated with aging, according to a new study from the University of Missouri School of Medicine. ---
**Author:** ![LeeJohn](https://www.rapamycin.news/user_avatar/www.rapamycin.news/leejohn/32/672_2.png) [@LeeJohn](https://www.rapamycin.news/u/LeeJohn)\ **Post date:** [May 29, 2022, 6:43am UTC](https://www.rapamycin.news/t/canagliflozin-another-top-longevity-drug/91/37 "2022-05-29T06:43:59Z")
May I know the acarbose dose you are taking? thank you ---
**Author:** ![RapAdmin](https://www.rapamycin.news/user_avatar/www.rapamycin.news/rapadmin/32/377_2.png) [@RapAdmin](https://www.rapamycin.news/u/RapAdmin)\ **Post date:** [June 6, 2022, 7:16pm UTC](https://www.rapamycin.news/t/canagliflozin-another-top-longevity-drug/91/38 "2022-06-06T19:16:54Z")
More good news on Canagliflozin: Lots of conflicts of interest in this research, but possibly interesting and in need of duplication by 3rd parties… ## Highlights • Canagliflozin reduced HbA1c and provided greater weight loss vs glimepiride. • Canagliflozin decreased serum leptin and increased serum adiponectin vs glimepiride. • Canagliflozin also decreased serum IL-6 and increased TNFα vs glimepiride. • No meaningful changes in biomarkers were seen with glimepiride. • Canagliflozin may improve adipose tissue function and cardiometabolic health. [https://www.sciencedirect.com/science/article/pii/S0026049518300416](https://www.sciencedirect.com/science/article/pii/S0026049518300416) ---
**Author:** ![RapAdmin](https://www.rapamycin.news/user_avatar/www.rapamycin.news/rapadmin/32/377_2.png) [@RapAdmin](https://www.rapamycin.news/u/RapAdmin)\ **Post date:** [June 8, 2022, 4:05am UTC](https://www.rapamycin.news/t/canagliflozin-another-top-longevity-drug/91/39 "2022-06-08T04:05:16Z")
Another interesting study… it would seem, since SGLT2 inhibitors reduce glucose spikes, the would also result in less osteoporosis: > > ---
**Author:** ![RapAdmin](https://www.rapamycin.news/user_avatar/www.rapamycin.news/rapadmin/32/377_2.png) [@RapAdmin](https://www.rapamycin.news/u/RapAdmin)\ **Post date:** [June 8, 2022, 5:06am UTC](https://www.rapamycin.news/t/canagliflozin-another-top-longevity-drug/91/40 "2022-06-08T05:06:59Z")
### Newer glucose‐lowering drugs and risk of dementia: A meta‐analysis of cardiovascular outcome trials > We included randomized placebo-controlled cardiovascular and renal outcome trials that reported all-cause dementia or vascular dementia (see definitions in Table [S1](https://agsjournals.onlinelibrary.wiley.com/doi/10.1111/jgs.17895#support-information-section)) associated with DPP-4 inhibitors, GLP-1RAs, and SGLT2 inhibitors among adults with and without T2D. > SGLT2 inhibitors were significantly associated with a decreased risk for vascular dementia (OR, 0.11; 95% CI, 0.02–0.66), compared with placebo. ### Full Paper: [https://agsjournals.onlinelibrary.wiley.com/doi/10.1111/jgs.17895](https://agsjournals.onlinelibrary.wiley.com/doi/10.1111/jgs.17895) [Previous page](https://www.rapamycin.news/t/canagliflozin-another-top-longevity-drug/91.md?page=1) [Next page](https://www.rapamycin.news/t/canagliflozin-another-top-longevity-drug/91.md?page=3)